Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pain mechanisms in multiple sclerosis.
Generation of an immortalized murine brain microvascular endothelial cell line as an in vitro blood brain barrier model.
Immune-Reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
Sphingolipids in ocular inflammation.
Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4.
[Current immunotherapy of multiple sclerosis].
Association of Neuromyelitis Optica With Severe and Intractable Pain.
MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas.
Longitudinal study of alexithymia and multiple sclerosis.
Closing the clinical-radiological paradox using the visual pathway in multiple sclerosis.
Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
A case with neuromyelitis optica mimicking Susac's syndrome.
AMPYRA® two-year safety data presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.
Lipopolysaccharide Upregulates the Expression of CINC-3 and LIX in Primary NG2 Cells.
Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis.
Cognitive performance of neuromyelitis optica patients: comparison with multiple sclerosis.
Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord.
Sulfatides in extracellular vesicles isolated from plasma of multiple sclerosis patients.
Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease
B-89Comparison of Driving Performance, Cognition, and Physical Symptoms in Individuals with Multiple Sclerosis and Healthy Controls.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis.

Pages